Our results are supported by additional in vivo studies performed with breast [34], endometrial [35] and pancreatic [36] cancer cells, which altogether point to ERRα as a specific target for the treatment of high energy demanding cells such as tumor cells. This evidence concerns the gene ESRRA and neoplasm.